The Newsroom

Investigations  /  10.19.2010

Robbins Umeda LLP Announces an Investigation of the Acquisition of King Pharmaceuticals, Inc. by Pfizer, Inc.

Robbins Umeda LLP has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by members of the Board of Directors (“Board”) of King Pharmaceuticals, Inc. (“King” or the “Company”) (NYSE: KG) in connection with their efforts to sell King to Pfizer, Inc. (“Pfizer”) (NYSE: PFE).  If the transaction is completed, King shareholders will receive $14.25 in cash for each share of King common stock they hold.

Robbins Umeda LLP’s investigation concerns whether King’s Board undertook a fair process to obtain fair consideration for all shareholders of King.  Specifically, our investigation concerns whether the Company’s Board breached their fiduciary duties to King shareholders by failing to adequately shop the Company before entering into the transaction with Pfizer.

If you are a shareholder of King, plan to continue to hold your shares, and would like more information about your rights as a shareholder, please contact attorney Gregory E. Del Gaizo at 800-350-6003 or by e-mail at info@robbinsarroyo.com.

Shareholder Information







Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.
I have read the disclaimer information.



Please Note: Neither the submission to nor the receipt of information by Robbins Arroyo LLP or one of its attorneys through this website constitutes an agreement by our firm to represent the individual and does not create an attorney-client relationship. Please do not send confidential or sensitive information through this website. This information should be communicated through a direct contact with an individual at the firm.

How can we help you?

CONTACT US TODAY | 1-800-350-6003 or info@robbinsarroyo.com

Tell us your concerns